BPMC (Common Stock) $100.610.00 (0.00%)
    03/21/18 4:00 p.m. ET
    Data provided by Nasdaq. Minimum 15
    minutes delay
    Refresh quote

    Corporate Profile

    Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company’s approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases.Read More

    Upcoming Events

    Blueprint Medicines AACR Event
    Sunday, April 15, 2018 7:30 p.m. CT

    View More


    Blueprint Medicines – Investor Presentation (January 2018)

    Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | Financial Tear Sheet